Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
Editor's Highlights | Breast Cancer Awareness Month
In support of Breast Cancer Awareness Month, Editor-in-Chief Dr. Larry Norton, Medical Director of the Evelyn H. Lauder Breast Center at Memorial Sloan Kettering Cancer Center, has curated a collection of research highlights from npj Breast Cancer. The collection includes research on prognostic markers, cancer genomics, metastasis, therapeutics, and more.
Patients with the most common form of breast cancer stand to benefit from taking a drug that blocks two cell cycle–regulating proteins in addition to hormonal therapy. In a phase III clinical trial, Stephen Johnston from the Royal Marsden NHS Foundation Trust in London, UK, and colleagues randomly gave 493 postmenopausal women with HR+/HER2− metastatic breast cancer a nonsteroidal aromatase inhibitor plus either a placebo or a drug called abemaciclib, a targeted inhibitor of CDK4 and CDK6. A planned interim analysis previously showed that abemaciclib was safe and effective. Johnson’s team now reports that abemaciclib nearly doubled the time women live without disease recurrence, from 15 months on placebo to 28 months on the drug. Additionally, responses were more common and lasted longer among women who received both abemaciclib and the hormonal therapy.